Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease
ConditionMoyamoya Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-60
SponsorBeijing Tiantan Hospital
About this trial
The purpose of this study is to comprehensively evaluate the risk factors for cognitive decline in patients with moyamoya disease, identify imaging target areas associated with cognitive damage in the brain, and explore the changes in brain structure and functional networks resulting from cerebral revascularization, as well as their relationship with cognitive improvement.
Eligibility criteria
Qualifiers
The admission cerebral angiography (DSA) examination fulfills the diagnostic criteria for moyamoya disease.
Please sign the informed consent form.
Participants must be between 18 and 60 years of age.
Disqualifiers
Patients with concurrent atherosclerosis, autoimmune diseases, meningitis, brain tumors, Down syndrome, craniocerebral trauma, prior radioactive head irradiation, or hyperthyroidism, which may result in secondary cerebrovascular lesions leading to symptoms associated with smoke syndrome.
Individuals younger than 18 years or older than 60 years.
Those with contraindications for magnetic resonance imaging.
Patients who are unable to complete cognitive brain assessments
Trial design
Treatments tested in this trial
- Revascularization
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov